Literature DB >> 22658491

Heparin-binding epidermal growth factor-like growth factor protects mesenchymal stem cells.

Daniel J Watkins1, Yu Zhou, Chun-Liang Chen, Amanda Darbyshire, Gail E Besner.   

Abstract

BACKGROUND: We have previously demonstrated that mesenchymal stem cell (MSC) administration protects the intestines from injury in a mouse model of intestinal ischemia/reperfusion injury. We have also shown that heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a potent intestinal cytoprotective agent in vivo that can protect the intestines by way of its effects on stem cells. The goal of the present study was to examine the effects of HB-EGF on both amniotic fluid (AF)- and bone marrow (BM)-derived MSCs in vitro.
METHODS: MSCs were isolated from the AF and BM of pan-EGFP mice, grown in MSC-specific culture medium, and purified by sequential passages according to their adherence properties. Pluripotency was confirmed by induced differentiation. After incubation of MSCs with HB-EGF, proliferation was quantified using the CyQuant cell proliferation assay kit under normoxic and anoxic conditions. Chemotaxis was quantified using the CHEMICON QCM cell migration kit, and apoptosis was determined using caspase-3 immunohistochemistry after exposure of the MSCs to anoxic stress.
RESULTS: AF-MSCs and BM-MSCs showed significantly increased proliferation and migration in response to HB-EGF. HB-EGF significantly protected AF-MSCs and BM-MSCs from anoxia-induced apoptosis. The proliferative and anti-apoptotic effects of HB-EGF were even more pronounced in AF-MSCs than in BM-MSCs.
CONCLUSIONS: These results have demonstrated that HB-EGF acts as a mitogenic and chemotactic agent for MSCs that protects MSCs from injury. These findings could have important implications for future experiments designed to use MSCs to protect the intestines from injury.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22658491      PMCID: PMC3434250          DOI: 10.1016/j.jss.2012.05.016

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  41 in total

1.  Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.

Authors:  K Elenius; S Paul; G Allison; J Sun; M Klagsbrun
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

2.  Isolation and characterization of a macrophage-derived heparin-binding growth factor.

Authors:  G Besner; S Higashiyama; M Klagsbrun
Journal:  Cell Regul       Date:  1990-10

3.  Hypoxia converts the myogenic action of insulin-like growth factors into mitogenic action by differentially regulating multiple signaling pathways.

Authors:  Hongxia Ren; Domenico Accili; Cunming Duan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 4.  Structure and function of heparin-binding EGF-like growth factor (HB-EGF).

Authors:  K M Davis-Fleischer; G E Besner
Journal:  Front Biosci       Date:  1998-03-01

5.  Cell sourcing for bone tissue engineering: amniotic fluid stem cells have a delayed, robust differentiation compared to mesenchymal stem cells.

Authors:  Alexandra Peister; Maria A Woodruff; Jarod J Prince; Derwin P Gray; Dietmar W Hutmacher; Robert E Guldberg
Journal:  Stem Cell Res       Date:  2011-03-21       Impact factor: 2.020

Review 6.  The role of the bone marrow derived mesenchymal stem cells in colonic epithelial regeneration.

Authors:  Gábor Valcz; Tibor Krenács; Ferenc Sipos; Katalin Leiszter; Kinga Tóth; Zsófia Balogh; Annamária Csizmadia; Györgyi Muzes; Béla Molnár; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2010-04-21       Impact factor: 3.201

7.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.

Authors:  S Higashiyama; J A Abraham; J Miller; J C Fiddes; M Klagsbrun
Journal:  Science       Date:  1991-02-22       Impact factor: 47.728

8.  Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice.

Authors:  Jian Zhang; Jian-Feng Gong; Wei Zhang; Wei-Ming Zhu; Jie-Shou Li
Journal:  J Biomed Sci       Date:  2008-09-02       Impact factor: 8.410

9.  Heregulin protects mesenchymal stem cells from serum deprivation and hypoxia-induced apoptosis.

Authors:  Chun Gui; Jian An Wang; Ai Na He; Tie Long Chen; Rong Hua Luo; Jun Jiang; Xin Yang Hu; Xiao Jie Xie
Journal:  Mol Cell Biochem       Date:  2007-07-10       Impact factor: 3.396

10.  Mesenchymal stem cells avoid allogeneic rejection.

Authors:  Jennifer M Ryan; Frank P Barry; J Mary Murphy; Bernard P Mahon
Journal:  J Inflamm (Lond)       Date:  2005-07-26       Impact factor: 4.981

View more
  5 in total

1.  HB-EGF augments the ability of mesenchymal stem cells to attenuate intestinal injury.

Authors:  Daniel J Watkins; Yu Zhou; Mika A B Matthews; Li Chen; Gail E Besner
Journal:  J Pediatr Surg       Date:  2014-01-31       Impact factor: 2.545

2.  Synergistic effects of HB-EGF and mesenchymal stem cells in a murine model of intestinal ischemia/reperfusion injury.

Authors:  Daniel J Watkins; Jixin Yang; Mika A B Matthews; Gail E Besner
Journal:  J Pediatr Surg       Date:  2013-06       Impact factor: 2.545

Review 3.  Stem cell therapy as a promising strategy in necrotizing enterocolitis.

Authors:  Si-Jia Di; Si-Yuan Wu; Tian-Jing Liu; Yong-Yan Shi
Journal:  Mol Med       Date:  2022-09-06       Impact factor: 6.376

4.  Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo.

Authors:  John B Shepard; Jae-Wook Jeong; Nita J Maihle; Sean O'Brien; Caroline N Dealy
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

5.  TGF-β1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In Vivo.

Authors:  Kevin Lynch; Oliver Treacy; Xizhe Chen; Nick Murphy; Paul Lohan; Md Nahidul Islam; Ellen Donohoe; Matthew D Griffin; Luke Watson; Steven McLoughlin; Grace O'Malley; Aideen E Ryan; Thomas Ritter
Journal:  Mol Ther       Date:  2020-05-30       Impact factor: 11.454

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.